Report
Luxury & Fashion: Dr Martens FY22 results: challenging macro is not a foregone conclusion for iconic brands
Luxury & FashionDr Martens FY22 results: challenging macro is not a foregone conclusion for iconic brands
Yesterday, Dr Martens unveiled FY22 results for the year ended 31st March: sales and aEBITDA topped CS expectations and company’s initial guidance despite Covid-related lockdowns in China. More importantly, Dr Martens shared a better-than-expected sales and aEBITDA FY23 outlook despite soaring inflation, backed by a robust order book that is confirmed at 85% of Dr Martens’ FY expectation. Once again, this momentum illustrates that against a context of tight spending, consumers focus on iconic brands which benefit from a DTC approach and legitimate positioning.
Provider
Bryan Garnier
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Cedric Rossi
Other Reports from Bryan Garnier
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.